Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer
Status:
Terminated
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29,
and will continue to compare combined hormonal therapy using the experimental aromatase
inhibitor (AI) atamestane combined with the FDA-approved anti-estrogen toremifene
(Fareston®), to the single agent FDA-approved aromatase inhibitor letrozole (Femara®) for the
treatment of advanced breast cancer. The purpose of this study is to determine whether
maximal estrogen suppression achieved via the combination of atamestane, plus toremifene
(Fareston®), is more effective than letrozole (Femara®) in delaying the growth of breast
cancer.